文献速递炎症性肠病

双生物制剂或小分子药物治疗炎症性肠病的系统评价与荟萃分析

Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-03-31

该系统评价与荟萃分析纳入30项研究、279例难治性炎症性肠病患者,评估双生物制剂或联合托法替尼治疗的安全性和有效性。汇总不良事件率31%、严重不良事件率6.5%,临床缓解率59%、内镜缓解率34%,12%需手术。结论认为该方案或可用于高度选择的难治性患者,但需更高质量数据支持。

要点

  • 双生物制剂或小分子联合治疗在难治性IBD中临床缓解率59%、内镜缓解率34%。
  • 不良事件率31%、严重不良事件率6.5%,12%患者需手术。
  • 因肠外表现而联合治疗的患者成功率更高。

核心结论

  • 双生物制剂或小分子治疗可能是高度选择的难治性IBD患者在专科中心的一种选择。
  • 在更广泛使用前需要更高质量的联合治疗数据。

研究设计与样本

  • 纳入报告同时使用生物制剂联合或联合托法替尼的队列研究或病例系列(>10例患者)。
  • 共纳入30项研究,报告279例患者中的288次双生物制剂或小分子治疗试验。

主要发现

  • 76%为克罗恩病,治疗中位持续时间24周(IQR25-IQR75 13-32)。
  • 双治疗主要适应证为医学难治性IBD(81%)和并发肠外表现或风湿病(12%)。
  • 最常见联合方案为TNF-α拮抗剂联合抗整合素(48%)、乌司奴单抗联合抗整合素(19%)。
  • 61%患者既往至少对联合方案中一种治疗失败。
  • 中位随访32周(IQR25-IQR75 24-52),汇总不良事件率31%(95%CI 13%-54%),严重不良事件率6.5%(95%CI 2.1%-13.1%)。

关键数值与推荐

  • 因肠外表现而接受双治疗的患者成功率更高。
  • 其他结局存在显著异质性。

临床怎么用

  • 在专科中心对高度选择的难治性IBD患者可考虑双生物制剂或小分子联合治疗。
  • 需关注不良事件和手术风险,并充分评估联合治疗的必要性。

局限性

  • 纳入研究为队列研究或病例系列,证据质量有限。
  • 其他结局存在显著异质性。
  • 需要更高质量的联合治疗数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: We conducted a systematic review and meta-analysis to summarize emerging data on the safety and effectiveness of dual biologic therapy in combination or with tofacitinib in patients with refractory inflammatory bowel disease (IBD). METHODS: Through a systematic search of multiple electronic databases through November 9, 2020, we identified cohort studies or case series (>10 patients) reporting the safety and effectiveness of simultaneous use of biologic agents in combination or with tofacitinib in patients with IBD. Rates of adverse events, clinical remission, and endoscopic remission were synthesized using pooled data, and we identified factors associated with successful dual therapy. RESULTS: We identified 30 studies reporting 288 trials of dual biologic or small molecule therapy in 279 patients (76% Crohn's disease; median duration of treatment 24 weeks (IQR25-IQR75 1332)). The main indications for dual therapy included medically refractory IBD (81%) and concurrent extra-intestinal manifestations or rheumatologic disease (12%). The most common combinations of dual therapy included tumor necrosis factor-α antagonists & anti-integrins (48%), ustekinumab & anti-integrins (19%); 61% of patients had previously failed at least one of the two therapies used in combination. Over a median follow-up of 32 weeks (IQR25-IQR75 24-52), pooled rates of adverse and serious adverse events were 31% (95% CI, 13%-54%) and 6.5% (95% CI, 2.1%-13.1%); pooled rates of clinical and endoscopic remission were 59% (95% CI, 42%-74%), and 34% (95% CI, 23%-46%), respectively. 12% (95% CI, 4%-24%) of patients required surgery. Rates of success were higher in patients on dual therapy due to EIM. Heterogeneity was not significant for endoscopic response (P = .88, I2 = 0%), endoscopic remission (P = .44, I2 = 0%), and malignancy (P = .87, I2 = 0%). However, significant heterogeneity existed for other outcomes. CONCLUSIONS: Dual biologic or small molecule therapy may be a possible option in highly selected, refractory IBD patients at specialized centers. Higher quality combination of therapies with a significant improvement in the quality of data is required prior to more widespread use.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Ahmed W, Galati J, Kumar A, et al. Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2021. PMID: 33798711. doi:10.1016/j.cgh.2021.03.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。